While much of the ASX 200 has recovered from early year instability, these two quality holdings remain lower relative to the start of the year.
It can often be difficult to find blue-chip shares that are significantly undervalued due to their long term proven track record.
However there are two right now that have fallen significantly in the last year.
Let's look at the likelihood of a bounce back for these two options.
Ampol Ltd (ASX: ALD)
Ampol is one of Australia's largest energy companies, sitting in the top 5 for market cap in that sector.
It is currently down 9.39% in 2025 and more than 20% over the last year.
Meanwhile, the S&P/ASX 200 Energy (ASX:XEJ) sector is up 3.72% for the year-to-date.
It's likely US tariffs played a role in the rocky start to the year.
However, it could now be undervalued as a result of the poor last 12 months.
Broker Bell Potter currently has a target price of $31.00. If Ampol shares reached this target it would be almost a 20% increase from its current price of $25.86.
Trading View also has a 12 month price target of $30.19, indicating Ampol shares could bounce back from current levels.
CSL Ltd (ASX: CSL)
One of Australia's largest ASX healthcare listed companies, CSL Limited is a global biotechnology company specialising in biopharmaceuticals. It has a focus on plasma-derived therapies, vaccines, and innovative biotechnology solutions.
Its previous half year results appeared to be below expectations, however it still reported healthy revenue and profits.
It appears the raised concerns about global economic stability may have contributed to the decline, as CSL has operations in both the U.S. and China.
At the time of writing, its share price is down more than 14% this year and is close to a 5-year low.
It could be a rare opportunity to buy low on a true blue-chip stock and Australia's largest health care stock by market capitalisation.
Brokers seem to agree.
Bell Potter currently has a buy recommendation on this ASX 200 company and a target price of $311.81.
That would indicate a 30.42% upside from its current share price of $239.1.
Macquarie also believes the company is well positioned to bounce back, with a recent outperform rating and $360.30 price target on its shares.
